Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression

Tumors evade the immune system by inducing inflammation. In melanoma, tumor-derived IL-1β drives inflammation and the expansion of highly immunosuppressive myeloid-derived suppressor cells (MDSCs). Similar in many tumors, melanoma is also linked to the downstream IL‐6/STAT3 axis. In this study, we observed that both recombinant and tumor-derived IL-1β specifically induce pSTAT3(Y705), creating a tumor-autoinflammatory loop, which amplifies IL-6 signaling in the human melanoma cell line 1205Lu. To disrupt IL-1β/IL-6/STAT3 axis, we suppressed IL-1β-mediated inflammation by inhibiting the NOD-like receptor protein 3 (NLRP3) using OLT1177, a safe-in-humans specific NLRP3 oral inhibitor. In vivo, using B16F10 melanoma, OLT1177 effectively reduced tumor progression (p< 0.01); in primary tumors, OLT1177 decreased pSTAT3(Y705) by 82% (p<0.01) and II6 expression by 53% (p<0.05). Disruption of tumor-derived NLRP3, either pharmacologically or genetically, reduced STAT3 signaling in bone marrow cells. In PMN-MDSCs isolated from tumor-bearing mice treated with OLT1177, we observed significant reductions in immunosuppressive genes such as Pdcd1l1, Arg1, Il10 and Tgfb1. In conclusion, the data presented here show that the inhibition of NLRP3 reduces IL-1β induction of pSTAT3(Y705) preventing expression of immunosuppressive genes as well as activity in PMN-MDSCs.

In advanced stage cancers, IL-6 is highly associated with disease progression (17)(18)(19). Canonically, IL-6 binds to either the membrane bound IL-6 receptor-a chain or soluble IL-6. Subsequently, these complexes bind ADAM10 or ADAM17 resulting in JAK/STAT activation and gene transcription. STAT3 is a transcription factor that regulates several unrelated biological processes such as maintenance of stem cell pluripotency, regeneration, autophagy, cell proliferation, and wound healing (18). In several cancers including melanoma, STAT3 is a prognostic marker predicting poor outcomes (20)(21)(22). STAT3 functions take place with the phosphorylation of tyrosine 705 (Y705) (23). Once phosphorylated, STAT3 dimerizes and enters the nucleus. There dimerized pSTAT3 binds specific DNA elements or binds with other transcription factors, modulating their activity (termed tethering) (24). Importantly, the trigger for Y705 phosphorylation is linked to IL-6 and Janus kinases.

Cell Culture
1205Lu and A357 human melanoma cells were cultured in RPMI, supplemented with 10% FBS, 100 units/ml penicillin, 0.1 mg/ml streptomycin. Cells were maintained in a humidified 5% CO 2 atmosphere at 37°C. Cells were detached from flasks using 0.25% Trypsin, 0.1% EDTA (Corning, Manassas, VA), centrifuged and resuspended in complete media. The cells were plated at 2.5x10 5 per well in a 24-wells plate and allowed to adhere overnight. The following day, the media were replaced with fresh RPMI, 10%FBS in presence and absence of the NLRP3 inhibitor OLT1177 (10 µM) (37). Supernatants were collected after 48 hours. In a separate set of experiments, IL-1b was added to the culture for stimulation (20 ng/ml; R&D Systems, Minneapolis, MN). Supernatants were collected after 24 hours. The murine melanoma cells B16F10 were cultured in DMEM GlutaMax, supplemented with 10%FBS, 100 units/ml penicillin, 0.1 mg/ml streptomycin. B16F10 NLRP3 knockout cells (B16F10 nlrp3 -/-) (Synthego, Redwood City, CA) were genetically edited by CRISPR-Cas9 technology using the following guide RNA sequence: UUCCUCUAUGGUAUGCCAGG. 48 hours posttransfection editing efficiency was determined at 96% compared to the control samples using the following PCR and sequencing primers: F:TTTCCTGCCTCCATCTCCCA and R: TTCAGTGAAGGCGGGTTTCC.

Cytokine Measurements
Cytokines were measured by specific DuoSet ELISAs according to the manufacturer's instructions (R&D Systems).

Western Blotting
1205Lu or A357 cells were cultured as previously described. Primary tumor and bone marrow cells were collected from tumor-tumor bearing. All cells were lysed in RIPA buffer (Sigma, St. Louis, MS, USA) supplemented with protease inhibitors (Roche, Indianapolis, IN), centrifuged at 13,000g for 20 min at 4°C and the supernatants were obtained. Protein concentration was determined in the clarified supernatant using Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA). Proteins were electrophoresed on Mini-PROTEAN TGX 4−20% gels (Bio-Rad Laboratories) and transferred to nitrocellulose 0.2 mm (GE Water & Process Technologies, Feasterville-Trevose, PA). Membranes were blocked in 5% rehydrated non-fat milk in PBS-Tween 0.5% for 1 hour at room temperature. Primary antibodies for STAT3 and pSTAT3(Y705) (CellSignaling, Danvers, MA) were used in combination with peroxidaseconjugated secondary antibodies. A primary antibody against b-actin (Santa Cruz Biotechnology, Dallas, TX) was used to assess protein loading.

In Vivo Model
Animal protocols were approved by the University of Colorado Animal Care and Use Committee. Wild type C57/Black 6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). B16F10 (2 x10 5 ) and B16F10 nlrp3 -/-(2 x10 5 ) cells were mixed with Matrigel (Corning) and then implanted subcutaneously (s.c.) in the hind quarter of mice. Mice were sacrificed 15 days after the plug instillation for molecular and cellular analysis. Tumor growth was recorded every three days. On day5 mice were treated daily by gavage of the NLRP3 specific inhibitor OLT1177 (generic dapansutrile, Olatec Therapeutics, LLC, New York, NY) at a concentration of 600mg/kg or the JAK inhibitor AZD1480 (Selleckchem, Houston, TX) (50mg/kg), starting on day 5 after melanoma cell implantation. Alternatively, OLT1177-enriched diet was used where denoted. Tumor volume was calculated using the formula V =1/2 (LxWxH) where V is tumor volume in cubic millimeters (mm 3 ). Dimensions were measured by electronic caliper on restrained mice. Tumors volumes were determined without knowledge of the experimental groups. Primary tumors and bone marrow were then assessed via western blotting or gene expression as described above.

T Cell MDSC Co-Culture
PMN-MDSCs were isolated from spleen of tumor-bearing mice described above using magnetic columns specific for MDSC isolation (Miltenyi Biotec, Germany). Naïve CD8+ T cells were isolated from spleen of non-tumor bearing mice using Mojosort kit (BioLegend) per manufacturer's instructions. Isolated CD8+ T cells were then stained with VPD solution. 50,000 T cells were then co-cultured with 50,000 MDSCs and in 96-well plates coated with 5ug/mL anti-CD3/28 and incubated for 3 days. On day 3, supernatants were removed and assessed for cytokines and T cell proliferation was determined by flow cytometry.

Public Database Gene Expression Analysis
Normalized gene expression data from the TCGA and project were downloaded from the gene expression profiling interactive analysis (GEPIA).

Interleukin-1b Induces pSTAT3 (Y705) in Human Metastatic Melanoma Cells
We have previously shown that metastatic melanoma cells display constitutively active NLRP3 resulting in spontaneous IL-1b production and release (16). Thus, we sought to assess whether tumor-derived IL-1b induces the IL-6/STAT3 signaling axis in melanoma cells. As shown in Figure 1A, we found that stimulation of the human metastatic melanoma 1205Lu cells with recombinant IL-1b increased IL-6 after 24 hours compared to the vehicle-treated control cells (p<0.001). Next, we assessed the effect of IL-1b on STAT3 activation. IL-1b significantly increased pSTAT3(Y705) ( Figures 1B, D), whereas there was no induction of total STAT3 in the same cells ( Figures 1C, D). We then determined whether reduction in IL-1b production via NLRP3 inhibition influenced IL-6 production and STAT3 phosphorylation. For this experiment, we used the synthetic, small molecule OLT1177, a specific NLRP3 inhibitor, which is safe and effective in humans (37,38). Spontaneous IL-1b production in 1205Lu cells was reduced 74% with NLRP3 inhibition by OLT1177 at 48 hours, confirming our previously published data (16) ( Figure 1E, p<0.001). The inhibition of NLRP3 activation and the subsequent suppression of IL-1b production resulted in a 28% reduction in IL-6 production ( Figure 1F, p<0.001). Analysis of the same cell lysates revealed a significant decrease in Y705 phosphorylation of STAT3 (p<0.05) without affecting the total levels of the transcription factor ( Figures 1G-I). These results were confirmed in another human metastatic melanoma cell line, A357. Consistently, Supplemental Figures 1A-I show that IL-1b induction of IL-6/STAT3 axis is indeed consistent amongst different metastatic melanoma cell lines.
These findings reveal that NLRP3-dependent, tumor-derived IL-1b induces autocrine IL-6 production, which leads to activation of canonical/nuclear functions of STAT3.

NLRP3 Inhibition Disrupts IL-1b-Induced IL-6/STAT3 Signaling in the Tumor Micro-Environment
To confirm our in vitro findings in vivo, we used the murine melanoma cell line B16F10. Briefly, mice were implanted with B16F10 and on day 5 daily oral treatment of OLT1177 or saline, in the control group, was started. As shown in Figure 2A, tumor size was reduced by 49% compared to vehicle treated mice (p<0.01). These data are in line with our previous reports, mice treated with OLT1177 revealed a 2-fold reduction in tumor volume compared to vehicle (p<0.01) (16). As shown in Supplement Figure 2A, daily treatment with the non-specific JAK inhibitor, AZD1480, exhibited a similar reduction in tumor growth when compared to vehicle. Western blot analysis of the primary tumors revealed that treatment with either OLT1177 or AZD1480 reduced constitutive STAT3 levels by 31% and 29%, respectively, but did not reach statistical significance ( Figure 2B). In contrast, there was a marked and highly significant (p<0.01) reduction in Y705 phosphorylated STAT3 by OLT1177 (82%) and AZD1480 (80%) compared to vehicle ( Figures 2C, D). No changes in Y705 phosphorylation of STAT3 were observed between OLT1177 or AZD1480 treatments ( Figures 2C, D).
We next examined the JAK-dependent, IL-6/STAT3 axis controlled by NLRP3. Genetic analysis of tumors from mice treated with OLT1177 or AZD1480 showed reduced gene expression of Il6 in comparison to the control group (both p<0.05) ( Figure 2E). In humans, analyses of the TCGA dataset revealed positive mRNA correlations from cutaneous melanoma biopsies for expression of NLRP3 and IL-6 (p=4.86e -20 ), IL-6 and the STAT3 target gene Socs3 (p=1.82e -62 ), IL-1b and Socs3 (p=1.71e -31 ) (Supplemental Figures 2B-D). Overall, these data confirm the in vitro observation and suggest the induction of IL-6/STAT3 following NLRP3 inflammasome activation as an integral driver of melanoma progression.

Tumor-NLRP3 Drives IL-6/STAT3 Signaling in the Bone Marrow
We previously observed that tumor NLRP3-dependent IL-1b production increases bone marrow production of both IL-1b and IL-6 (16). Therefore, we sought to assess whether tumor-associated NLRP3 activity also affects the IL-1b/IL-6/STAT3 axis in host myeloid cells. To investigate this, mice were implanted with B16F10 and treated as described in Figure 2A. On day 15 when tumors are in exponential growth, bone marrow cells were analyzed by Western blot. As shown in Figures 3A-C, tumor-bearing mice receiving OLT1177 exhibited significantly less constitutive STAT3 (p<0.05) and pSTAT3(Y705) (p<0.05) in the bone marrow compared to vehicle-treated mice. Next, we confirmed the role of tumor-derived NLRP3 by implanting wild-type B16F10 or B16F10 deficient of NLRP3 (B16F10 nlrp3 -/-). After 15 days, we analyzed bone marrow-derived cells as described above. As shown in Figures 3D-F, bone marrow-derived cells from mice implanted with B16F10 nlrp3 -/cells revealed significantly less total STAT3 (p<0.05) and pSTAT3(Y705) (p<0.05) compared to the cells isolated from mice implanted with wild-type B16F10. In addition to our published data (16), these results posit NLRP3 as a key driver of STAT3 in melanoma-associated inflammation.

pSTAT3(Y705) Regulates PMN-MDSCs Immunosuppressive Gene Expression
Inhibition of tumor-derived NLRP3 results in reduced PMN-MDSCs expansion from the bone marrow and less infiltrating MDSCs in the TME (16). Thus, we sought to determine if the reduction in IL-6/STAT3 activation observed following NLRP3 inhibition ( Figure 3) affects expression of genes associated with the immunosuppressive activity of PMN-MDSCs. Mice were implanted with B16F10 and on day 5 treated with daily oral OLT1177 or saline. PMN-MDSCs from tumor-bearing mice treated with vehicle or OLT1177 were isolated from the bone marrow and spleen using flow cytometry and assessed for gene expression (Supplemental Figure 3). As shown in Figure 4A, bone marrow and spleen-derived PMN-MDSCs from mice treated with OLT1177 revealed a substantial reduction in the  expression of genes associated with nuclear STAT3 activity, namely, Socs3 and Klf4, confirming reduced STAT3 activity. These same cells were also assessed for the expression of immunosuppressive genes, such as pdcd1l1 (PD-L1), Arg1 (Arginase 1), Il10 (IL-10) and Tgfb1 (TGF-b1). With the exception of Il10, these genes were significantly reduced in the bone marrow of mice treated with OLT1177, for example, Pdcd1l1 (86%, p<0.01), Arg1 (80%, p<0.01) and Tgfb1 (65%, p<0.05) ( Figure 4B). In the spleen ( Figure 4C), we also observed significant decreased levels of Pdcd1l1 (74%, p<0.01), Arg1 (83%, p<0.01) and Tgfb1 (69%, p<0.05) as well as a non-significant decrease in, Il10. To confirm the role of STAT3 in these NLRP3mediated changes of PMN-MDSCs, tumor-bearing mice were treated with AZD1480 and PMN-MDSCs were assessed as described above. As shown in Supplemental Figures 4A, B, PMN-MDSCs obtained from AZD1480-treated mice exhibited decreased immunosuppressive gene expression compared to vehicle, similar to that observed in OLT1177-treated mice. We next compared relative gene expression from bone marrowderived PMN-MDSCs to spleen-derived PMN-MDSCs.

Figures 4D, E depicts fold-change increases in immuno
suppressive gene expression upon migration in the peripherical tissues as well as relative Cq values. Overall, these data show that inhibiting tumor-NLRP3 alone is sufficient to reduce IL-6/ STAT3 activation, resulting in the reduction of immuno suppressive gene expression in PMN-MDSCs. We next examined the effect of NLRP3 inhibition on MDSCs function in ex vivo conditions. Briefly, naïve CD8+ T cells were isolated from non-tumor-bearing mice and co-cultured with spleen MDSCs isolated from tumor-bearing mice fed standard or OLT1177 diet. On day 3, T cell proliferation was determined using flow cytometry and supernatants were assessed for T cell associated cytokines. Figure 4F depicts the levels of IL-2, IFNg and TNFa secretion from the co-cultures described above. Supernatants from co-cultures containing MDSCs isolated from mice treated with OLT1177 revealed significantly higher levels of IL-2 (p<0.05), IFNg (p<0.05) and TNFa (p<0.01) compared to co-cultures containing MDSCs from mice fed the standard diet ( Figure 4F). Consistently, T cell proliferation was significantly higher in co-cultures containing MDSCs isolated  from mice treated with OLT1177 ( Figure 4G). Taken together, these data suggest tumor-NLRP3 as a potential target to suppress MDSCs, which ultimately dampen cytotoxic T cell functions.

DISCUSSION
Although it is well established that tumor-induced inflammation drives immunosuppression (4,8), specific molecular mechanism(s) that account for the inflammation are not fully understood. In this study, we elucidated a novel mechanism that demonstrates how NLRP3 activity in melanoma drives inflammation resulting in increased expression of immunosuppressive genes in MDSCs. Using a mouse model of melanoma, we report here that NLRP3 activation induces IL-1b-mediated IL-6 production resulting in STAT3 activation. We also observed that with specific inhibition of NLRP3, both tumor volume and STAT3 signaling in the TME are significantly reduced. These observations are consistent with the concept of tumor-derived inflammation promoting tumor progression and that IL-1b induces IL-6/STAT3 activation in melanoma. As depicted in Figure 5 and in line with our previous findings, tumor-derived constitutive NLRP3 activity induces IL-1b and IL-6 in bone marrow and spleen cells (16), we show that tumorbearing mice treated with OLT1177 reveal reductions in both total STAT3 as well as pSTAT3 (Y705) in bone marrow cells. We conclude an NLRP3-mediated autoinflammatory loop drives IL-6/ STAT3 regulated immunosuppressive gene expression. Thus, NLRP3 is a therapeutic target to reverse canonical STAT3 mediated cancer promotion. The implication of tumor-derived NLRP3 driving IL-1b-IL-6-STAT3 signaling was confirmed in mice implanted with NLRP3 deficient B16F10 cells (B16F10 nlrp3 -/-). Using NLRP3 deficient B16F10 cells, we observed similar reductions of STAT3 and pSTAT3 (Y705) comparable to those of OLT1177 treatment. Upon knock-down of NLRP3 in the tumor, IL-1b processing is arrested and, therefore mature IL-1b-induced IL-6/STAT3 axis is no longer being amplified. With reduced IL-1b activity, there is less tumor-derived IL-1b and IL-6 activity on bone marrow cells and ultimately decreased STAT3 activity in this cell population ( Figure 5), supporting our previous findings that tumor-NLRP3 activity induces IL-1b and IL-6 in the bone marrow (16).
Linking tumor-NLRP3 induction of IL-6/STAT3 to immunosuppression, we assessed PMN-MDSCs in bone marrow and spleen from tumor-bearing mice treated with OLT1177. Disruption of STAT3 transcriptional activity was associated with the reduction of STAT3 target genes Socs3 and Klf4. Mice treated with OLT1177 revealed the IL-1b-dependent role of STAT3 in promoting the levels of immunosuppressive genes. We show marked reductions in Pdcd1l1, Arg1, Il10 and Tfgb1 in PMN-MDSCs from bone marrow and spleen of tumorbearing mice. In order to show the role of JAK-mediated STAT3 phosphorylation in PMN-MDSCs, we treated mice with AZD1480 and observed similar reductions in gene expression as we observed with OLT1177 treatment. These findings implicate IL-1b-dependent IL-6/STAT3 signaling as an integral driver of tumor-induced inflammation that promotes immunosuppressive gene expression of PMN-MDSCs. These data also provide new insights into therapeutic approaches to disrupt tumor immune evasion offered by NLRP3 inhibitors in melanoma ( Figure 5). Cytokines produced by tumors change not only immune cell function in the TME, but also the expansion and activation of myeloid cells in the bone marrow (19,29,39). We recently reported that constitutively active NLRP3 in melanoma cells induces IL-1b and IL-6 in the host, resulting in the expansion of MDSCs (16). In line with those findings, in the present study we demonstrate that elevated IL-6 induces STAT3 activation, which is an established pro-tumor mechanism present in many cancers for MDSC activation as well as gene expression (32,36). Of note, other STATs have been implicated in melanoma progression, such as STAT5 (40). This prior study showed activity of STAT5 was mediated in park by JAK1, of which IL-6 is a known activator, therefore we cannot rule out other STAT activity. Notably, activation of STAT3 in cancer has mostly been attributed to loss of function of STAT3 regulatory genes, but not by increased activity of upstream inducers of IL-6 such as NLRP3 (36,41,42). Here, we link NLRP3 activity in melanoma cells to the IL-1b induced-IL-6/STAT3 axis, thus providing an additional mechanism to target STAT3 signaling in melanoma. Our study also expands on this pathway in that NLRP3 inhibition reduces transcriptional activity of STAT3; thus we observed markedly  lower gene expression in PMN-MDSCs, namely: Pdcd1l1 (PD-L1), Arg1, Il10 and Tgfb1. Moreover, NLRP3 inhibition reduced the immunosuppressive potential as shown by increased T cell proliferation and production IL-2, IFNg and TNFa in co-culture. These findings suggest PMN-MDSCs are reliant on tumor inflammatory signals for upregulation of immunosuppressive genes, which in turn, dictate function. This concept is of particular importance for immunotherapy. Levels of MDSCs have been proposed as a predictive marker for response to immunotherapy (43,44). Specifically, in melanoma Pdcd1l1, the gene encoding Programed Death-Ligand1 (PD-L1), is highly expressed in MDSCs and elevated levels of circulating MDSCs may serve as an indicator of checkpoint inhibition and reduced tumor growth (44)(45)(46)(47). However, a recent study reported that anti-PD-1 therapy increased melanoma-NLRP3 activity, resulting in increased PD-L1 expression in the tumor (48). Nevertheless, upon knockdown of tumor-derived NLRP3, tumor progression markedly slowed with anti-PD-1, resulting in decreased PMN-MDSC infiltration into the TME (47). Alternatively, we observed NLRP3 activation in B16F10 metastatic melanoma independent of anti-PD-1 therapy. Importantly, a consequence of NLRP3 activation in the tumor are alterations in the systemic host immune response, a concept that is highly relevant in immunotherapeutic approaches targeting inflammatory tumors. Here, we report how tumor-NLRP3 activity promotes IL-6/ STAT3 signaling in the bone marrow, which then regulates immunosuppressive gene expression in PMN-MDSCs resulting in a defunct cell population.
As STAT3 phosphorylation by the JAK1/2 is well known in cancer, we used AZD1480, which suppress JAK1/2 (49,50), to demonstrate that phosphorylation of STAT3 at Y705 is dependent of JAK1/2. We show the reduction in pSTAT3 (Y705) in Figure 2 and observed a significant reduction in B16F10 tumor growth in mice treated with AZD1480 (Supplemental Figure 1A). Several JAK1/2 inhibitors are used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis. Tofacitinib, ruxolitinib, baricitinib and upadacitinib are JAK1/2 inhibitors also used in alopecia areata (51,52). JAK1/2 inhibitors reduce several cytokines; among these are IL-2, IL-15, IL-12/23 IL-6, IFNg, IFNa, IL-10 and G-CSF. Upon binding to their respective type 1 and type 2 receptors, JAKs are recruited to the cytosolic domains resulting in the phosphorylation of STATs, initiation of transcription and subsequent biological activities of the respective cytokines. In human peripheral blood mononuclear cells from healthy donors, JAK inhibitors added in vitro reduced STAT3 (Y705) phosphorylation (53). Although the benefit of reducing STAT3 phosphorylation at Y705 results in suppression of transcriptional activation of several cytokines in autoimmune diseases, this mechanism is also valid in treatment of cancer. For example, myeloproliferative neoplasms such as chronic lymphocytic leukemia (54) and solid tumors such as colorectal cancer (55) are treated with JAK inhibitors. In patients with autoimmune diseases or cancer, JAK inhibitors are associated with serious side effects such as anemia, nausea, vomiting, weight loss, myalgia, herpes zoster, neutropenia and low levels of circulating lymphocytes. JAK inhibitors are also a risk for life-threatening thromboembolic events such as deep venous thrombosis and pulmonary embolism (56). Upadacitinib treatment in rheumatoid arthritis resulted in hepatic dysfunction in 7.6% of the patients (57). By comparison, patients treated with oral OLT1177 for gout flares (38) or heart failure (58) report no side effects but rather an increase in well-being.
Altogether, these findings reveal how metastatic melanoma cells amplify IL-6 signaling through an NLRP3-mediated auto inflammatory loop, which in turn, drives IL-6/STAT3 regulated immunosuppressive gene expression in PMN-MDSCs. The proposed pathway elicits NLRP3 as a therapeutic target to reverse canonical STAT3 mediated mechanisms of cancer promotion.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The animal study was reviewed and approved by University of Colorado Animal Care and Use Committee.

AUTHOR CONTRIBUTIONS
IT designed the research. IT, AD, MB and NP carried out the research. IT, AD, CM, and CD, analyzed the data. LJ critically read the paper. IT, CM, and CD wrote the paper. All authors contributed to the article and approved the submitted version.

FUNDING
These studies are supported by NIH Grant AI-15614 (to CD), the Interleukin Foundation, and Olatec Industries. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. (B) Mean ± SEM of relative mRNA expression of Pdcd1l1, Arg1, Il10 and Tgfb1 from PMN-MDSCs isolated from bone marrow of mice described above (N=2, pooled from 4 mice/group. 2 independent experiments). *p < 0.05, **p < 0.001, ***p < 0.001.